评估质母细胞瘤中孕激素受体调节:从体外和动物模型到人类试点协议
Denisse Arcos-Montoya1, Patricia García-López2, Talia Wegman-Ostrosky3
1Departamento de Medicina Genómica y Toxicología Ambiental, Instituto de Investigaciones Biomédicas, Universidad Nacional Autónoma de México, Mexico City, Mexico.
Cancer biology & therapy
|December 24, 2025
概括
米菲普里斯 (MF) 通过调节孕激素受体 (PR) 有效地降低了质母细胞瘤 (GB) 细胞活力和瘤生长. 这种重新设计的药物在GB治疗中有望改善患者的生存率和生活质量.
科学领域:
- 神经瘤学神经瘤学
- 内分泌学 在内分泌学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 质瘤,包括质母细胞瘤 (GB),是具有不良预后的侵袭性脑瘤.
- 孕激素受体 (PR) 的激活促进了质瘤的进展.
- 目前的治疗方法为质母细胞瘤患者提供了有限的生存益处.
研究的目的:
- 调查PR抗剂米费普里斯 (MF) 在治疗质母细胞瘤方面的疗效.
- 评估MF对质瘤细胞活力,球体形成和瘤生长的作用in vitro和in vivo.
- 评估MF作为GB的辅助疗法的临床安全性和生存益处.
主要方法:
- 在质瘤细胞系 (U87,U251,C6) 中通过免疫光和Western Blot.评估PR表达和异型.
- 使用LC/MS的量化孕激素及其代谢物.
- 确定了MF对细胞活力,非瘤细胞和3D球体形成的影响;评估了老鼠模型中的体内瘤生长,并进行了一项试点临床试验.
主要成果:
- PR主要是核的,U87细胞表现出高水平的PR-B;U251细胞合成了5α-DHP.
- 毫米显著降低了质瘤细胞的活力和球体形成,而不会影响非瘤细胞,并且在体内依赖剂量下降了瘤体积.
- 从临床上看,MF使患者的生存时间从165天提高到588天,提高了生活质量,并证明了药理安全性.
结论:
- 米费普里斯有效地抑制了质母细胞瘤细胞活力,球体形成和瘤生长.
- 作为用于质母细胞瘤治疗的重用药物,MF显示出显著的治疗潜力.
- 多发性是一种安全的辅助治疗质母细胞瘤,大大提高了患者的存活率.
相关概念视频
02:43Mouse Models of Cancer Study
Mice have long served as models for studying human biology and pathology because of their phylogenetic and physiological similarity with humans. They are also easy to maintain and breed in the laboratory, and hence, many inbred strains are now available for research. Studies on mice have contributed immeasurably to our understanding of cancer biology.
The development of transgenic, knockout, and knock-in mice has led to an exponential increase in their use as model organisms in research,...
The development of transgenic, knockout, and knock-in mice has led to an exponential increase in their use as model organisms in research,...
02:43Mouse Models of Cancer Study
Mice have long served as models for studying human biology and pathology because of their phylogenetic and physiological similarity with humans. They are also easy to maintain and breed in the laboratory, and hence, many inbred strains are now available for research. Studies on mice have contributed immeasurably to our understanding of cancer biology.
The development of transgenic, knockout, and knock-in mice has led to an exponential increase in their use as model organisms in research,...
The development of transgenic, knockout, and knock-in mice has led to an exponential increase in their use as model organisms in research,...
01:25Mutagenicity and Carcinogenicity
Mutagenicity and carcinogenicity refer to the ability of drugs to cause genetic defects and induce cancer, respectively. The International Agency for Research on Cancer (IARC) classifies agents into four groups based on their carcinogenic potential. Group 1 agents are known human carcinogens; group 2A agents are probably carcinogenic to humans; group 3 agents lack data to support their role in carcinogenesis; and group 4 includes agents for which data support that they are not likely to be...